Search

The direct analysis of 3D Optical Coherence Tomography (OCT) volumes enables deep learning models (DL) to learn spatial structural information and discover new bio-markers that are relevant to glaucoma. Downsampling 3D input volumes is the state-of-art solution to accommodate for the limited number of training volumes as well as the available computing resources. However, this limits the network's ability to learn from small retinal structures in OCT volumes. In this paper, our goal is to improve the performance by providing guidance to DL model during training in order to learn from finer ocular structures in 3D OCT volumes. Therefore, we propose an end-to-end attention guided 3D DL model for glaucoma detection and estimating visual function from retinal structures. The model consists of three pathways with the same network architecture but different inputs. One input is the original 3D-OCT cube and the other two are computed during training guided by the 3D gradient class activation heatmaps. Each pathway outputs the class-label and the whole model is trained concurrently to minimize the sum of losses from three pathways. The final output is obtained by fusing the predictions of the three pathways. Also, to explore the robustness and generalizability of the proposed model, we apply the model on a classification task for glaucoma detection as well as a regression task to estimate visual field index (VFI) (a value between 0 and 100). A 5-fold cross-validation with a total of 3782 and 10,370 OCT scans is used to train and evaluate the classification and regression models, respectively. The glaucoma detection model achieved an area under the curve (AUC) of 93.8% compared with 86.8% for a baseline model without the attention-guided component. The model also outperformed six different feature based machine learning approaches that use scanner computed measurements for training. Further, we also assessed the contribution of different retinal layers that are relevant to glaucoma. The VFI estimation model achieved a Pearson correlation and median absolute error of 0.75 and 3.6%, respectively, for a test set of size 3100 cubes. [ABSTRACT FROM AUTHOR]

Optical coherence tomography (OCT) based measurements of retinal layer thickness, such as the retinal nerve fibre layer (RNFL) and the ganglion cell with inner plexiform layer (GCIPL) are commonly employed for the diagnosis and monitoring of glaucoma. Previously, machine learning techniques have relied on segmentation-based imaging features such as the peripapillary RNFL thickness and the cup-to-disc ratio. Here, we propose a deep learning technique that classifies eyes as healthy or glaucomatous directly from raw, unsegmented OCT volumes of the optic nerve head (ONH) using a 3D Convolutional Neural Network (CNN). We compared the accuracy of this technique with various feature-based machine learning algorithms and demonstrated the superiority of the proposed deep learning based method. Logistic regression was found to be the best performing classical machine learning technique with an AUC of 0.89. In direct comparison, the deep learning approach achieved a substantially higher AUC of 0.94 with the additional advantage of providing insight into which regions of an OCT volume are important for glaucoma detection. Computing Class Activation Maps (CAM), we found that the CNN identified neuroretinal rim and optic disc cupping as well as the lamina cribrosa (LC) and its surrounding areas as the regions significantly associated with the glaucoma classification. These regions anatomically correspond to the well established and commonly used clinical markers for glaucoma diagnosis such as increased cup volume, cup diameter, and neuroretinal rim thinning at the superior and inferior segments. [ABSTRACT FROM AUTHOR]

Spectral-domain optical coherence tomography (SDOCT) is a non-invasive imaging modality that generates high-resolution volumetric images. This modality finds widespread usage in ophthalmology for the diagnosis and management of various ocular conditions. The volumes generated can contain 200 or more B-scans. Manual inspection of such large quantity of scans is time consuming and error prone in most clinical settings. Here, we present a method for the generation of visual summaries of SDOCT volumes, wherein a small set of B-scans that highlight the most clinically relevant features in a volume are extracted. The method was trained and evaluated on data acquired from age-related macular degeneration patients, and “relevance” was defined as the presence of visibly discernible structural abnormalities. The summarisation system consists of a detection module, where relevant B-scans are extracted from the volume, and a set of rules that determines which B-scans are included in the visual summary. Two deep learning approaches are presented and compared for the classification of B-scans—transfer learning and de novo learning. Both approaches performed comparably with AUCs of 0.97 and 0.96, respectively, obtained on an independent test set. The de novo network, however, was 98% smaller than the transfer learning approach, and had a run-time that was also significantly shorter. [ABSTRACT FROM AUTHOR]

Clinical trials consume the latter half of the 10 to 15 year, 1.5–2.0 billion USD, development cycle for bringing a single new drug to market. Hence, a failed trial sinks not only the investment into the trial itself but also the preclinical development costs, rendering the loss per failed clinical trial at 800 million to 1.4 billion USD. Suboptimal patient cohort selection and recruiting techniques, paired with the inability to monitor patients effectively during trials, are two of the main causes for high trial failure rates: only one of 10 compounds entering a clinical trial reaches the market. We explain how recent advances in artificial intelligence (AI) can be used to reshape key steps of clinical trial design towards increasing trial success rates. Suboptimal patient selection and recruiting techniques, paired with the inability to monitor and coach patients effectively during clinical trials, are two of the main causes for high trial failure rates. High failure rates of clinical trials contribute substantially to the inefficiency of the drug development cycle, in other words the trend that fewer new drugs reach the market despite increasing pharma R&D investment. This trend has been observed for decades and is ongoing. AI techniques have advanced to a level of maturity that allows them to be employed under real-life conditions to assist human decision-makers. AI has the potential to transform key steps of clinical trial design from study preparation to execution towards improving trial success rates, thus lowering the pharma R&D burden. [ABSTRACT FROM AUTHOR]